BiomX Inc. Shareholders Approve 2026 Equity Incentive Plan at Special Meeting

Key Highlights for Investors:

• Date of Event: April 10, 2026
• Event: Special Meeting of Stockholders
• Key Proposal Approved: Adoption of the BiomX Inc. 2026 Equity Incentive Plan
• Potential Price Sensitivity: The approval of a substantial new equity plan could impact future dilution and is material for valuation models.

Details of the Special Meeting and Voting Results

BiomX Inc. (NYSE American: PHGE), a biological products company, held a special meeting of stockholders on April 10, 2026. At the meeting, shareholders voted on key matters outlined in the proxy statement dated March 25, 2026.

Voting Participation

• Outstanding Shares as of Record Date (March 23, 2026): 6,543,516 shares, each entitled to one vote.
• Shares Represented at Meeting: 3,409,604 votes, either in person or by proxy (over 52% participation).
• No Broker Non-Votes: All proposals were non-routine matters, meaning all votes were counted and there were no broker non-votes.

Key Proposal: 2026 Equity Incentive Plan

The sole proposal submitted for shareholder approval was the BiomX Inc. 2026 Equity Incentive Plan. This plan is significant for the following reasons:

• Maximum Shares Issuable: Up to 1,390,000 shares of common stock can be issued under the plan.
• Automatic Annual Increase: Each year, for ten years, the plan allows an automatic increase to the share pool, equal to 4% of the total number of common shares outstanding as of December 31 of the prior year.
• Plan Duration: 10 years (with annual increases each year).

This plan is designed to provide long-term equity-based incentives to management, employees, directors, and other contributors, aligning interests between shareholders and company leadership.

Voting Results

Outcome: The proposal was overwhelmingly approved, with over 99% of votes cast in favor.

Potential Implications for Shareholders

• Possible Share Dilution: The approval of the equity plan authorizes the company to issue a significant number of new shares over the next decade. While equity incentives are a standard practice to attract and retain talent, they can dilute existing shareholders if exercised at scale. Investors should consider the possible impact on earnings per share and ownership percentages over time.
• Alignment of Interests: Equity incentives can strengthen alignment between company leadership and shareholders, potentially supporting long-term value creation.
• Future Share Price Impact: The adoption of a large equity plan is a material development. Market reaction will depend on investor confidence in management’s ability to drive growth that justifies the possible future dilution.

Other Notable Information

• Company Status: BiomX Inc. is not classified as an emerging growth company.
• Main Security: Common Stock, \$0.0001 par value per share, trading under the symbol PHGE on the NYSE American.
• Company Details: Incorporated in Delaware. EIN: 82-3364020. Headquarters: 850 New Burton Road, Suite 201, Dover, DE 19904.
• Previous Name: Formerly known as Chardan Healthcare Acquisition Corp. (name changed on April 30, 2018).

Conclusion

The approval of the 2026 Equity Incentive Plan is a noteworthy development for BiomX Inc. shareholders. While it provides flexibility for the company to incentivize talent, investors should closely monitor future equity issuances and their potential effect on dilution and share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a professional advisor before making investment decisions. The information presented is based on publicly available filings and may be subject to change.

View BiomX Inc. Historical chart here